p53-Armed Oncolytic Virotherapy Improves Radiosensitivity in Soft-Tissue Sarcoma by Suppressing BCL-xL Expression

Area of Science:

• Oncology
• Virology
• Radiation Oncology

Background:

• Soft-tissue sarcoma (STS) is a rare, heterogeneous cancer often resistant to current treatments.
• Novel therapeutic strategies are crucial for improving patient outcomes in STS.
• Oncolytic adenoviruses show promise as cancer therapeutics.

Purpose of the Study:

• To evaluate the combined antitumor effects of OBP-702 and ionizing radiation in human STS cells.
• To investigate the mechanisms underlying the synergistic effects of this combination therapy.

Main Methods:

• In vitro and in vivo studies using human STS cell lines (HT1080, NMS-2, SYO-1).
• Treatment with OBP-702 (a telomerase-specific oncolytic adenovirus) and ionizing radiation.
• Assessment of apoptosis, B-cell lymphoma-X large (BCL-xL) expression, and tumor growth suppression.

Main Results:

• OBP-702 synergistically enhanced the antitumor effects of ionizing radiation against STS cells.
• The combination therapy suppressed BCL-xL expression and increased radiation-induced apoptosis.
• In vivo experiments demonstrated significant suppression of STS tumor growth with the combination therapy.

Conclusions:

• OBP-702 in combination with ionizing radiation exhibits significant antitumor activity against STS.
• This combination strategy holds promise for enhancing radiosensitivity and improving the prognosis of STS patients.